Literature DB >> 24607622

Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography.

François Durand1, Sophie Buyse2, Claire Francoz3, Cédric Laouénan4, Onorina Bruno5, Jacques Belghiti6, Richard Moreau3, Valérie Vilgrain7, Dominique Valla3.   

Abstract

BACKGROUND & AIMS: Waiting-list mortality in patients with cirrhosis and a relatively low MELD score is a matter of concern. The aim of this study was to determine whether a marker of muscle waste could improve prognostication.
METHODS: A pre-MELD cohort (waiting time-based allocation; n=186) and a MELD-era cohort (n=376) were examined. At evaluation, transversal psoas muscle thickness (TPMT) was measured on a computed tomography (CT) image at the level of the umbilicus. In the pre-MELD cohort, TPMT/height (mm/m) and the MELD score were entered in univariate and multivariate models to predict mortality after registration. Applicability of pre-MELD findings was tested in the MELD-era.
RESULTS: In the pre-MELD cohort, the MELD score and TPMT/height were significantly associated with mortality. The discrimination of a score combining MELD and TPMT/height (MELD-psoas) was 0.84 (95% CI, 0.62-0.95). In the MELD-era, TPTM/height was significantly associated with mortality, independent of the MELD and MELD-Na scores. There was a 15% increase in mortality risk per unit decrease in TPMT/height. The discrimination of MELD-psoas score (0.82; 95% CI, 0.64-0.93) was superior to that of the MELD score and similar to that of the MELD-Na score. In patients with refractory ascites, mortality was significantly higher when TPMT/height was <16.8 mm/m (42% vs. 9%, p=0.02).
CONCLUSIONS: TPMP/height on CT at the level of the umbilicus, an objective marker of muscle waste, may be predictive of mortality in cirrhotic patients, independent of the MELD and MELD-Na scores. It may help to better assess the prognosis of patients with refractory ascites.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Liver transplantation; MELD score; Refractory ascites; Sarcopenia

Mesh:

Year:  2014        PMID: 24607622     DOI: 10.1016/j.jhep.2014.02.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  96 in total

1.  A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.

Authors:  Elizabeth J Carey; Jennifer C Lai; Christopher Sonnenday; Elliot B Tapper; Puneeta Tandon; Andres Duarte-Rojo; Michael A Dunn; Cynthia Tsien; Eric R Kallwitz; Vicky Ng; Srinivasan Dasarathy; Matthew Kappus; Mustafa R Bashir; Aldo J Montano-Loza
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

2.  Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.

Authors:  Rahima A Bhanji; Carlos Moctezuma-Velazquez; Andres Duarte-Rojo; Maryam Ebadi; Sunita Ghosh; Christopher Rose; Aldo J Montano-Loza
Journal:  Hepatol Int       Date:  2018-06-07       Impact factor: 6.047

3.  Impact of muscle wasting on survival in patients with liver cirrhosis.

Authors:  Maria Kalafateli; Christos Konstantakis; Konstantinos Thomopoulos; Christos Triantos
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

4.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

5.  Early post-transplant survival: Interaction of MELD score and hospitalization status.

Authors:  Therese Bittermann; George Makar; David S Goldberg
Journal:  J Hepatol       Date:  2015-04-07       Impact factor: 25.083

6.  Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis.

Authors:  Kazufumi Kobayashi; Hitoshi Maruyama; Soichiro Kiyono; Sadahisa Ogasawara; Eiichiro Suzuki; Yoshihiko Ooka; Tetsuhiro Chiba; Naoya Kato; Tadashi Yamaguchi
Journal:  J Gastroenterol       Date:  2017-08-18       Impact factor: 7.527

7.  A multicenter study to define sarcopenia in patients with end-stage liver disease.

Authors:  Elizabeth J Carey; Jennifer C Lai; Connie W Wang; Srinivasan Dasarathy; Iryna Lobach; Aldo J Montano-Loza; Michael A Dunn
Journal:  Liver Transpl       Date:  2017-05       Impact factor: 5.799

8.  Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization.

Authors:  Michael A Dunn; Deborah A Josbeno; Amit D Tevar; Vikrant Rachakonda; Swaytha R Ganesh; Amy R Schmotzer; Elizabeth A Kallenborn; Jaideep Behari; Douglas P Landsittel; Andrea F DiMartini; Anthony Delitto
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

Review 9.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

Review 10.  Nutritional assessment in cirrhotic patients with hepatic encephalopathy.

Authors:  Fernando Gomes Romeiro; Laís Augusti
Journal:  World J Hepatol       Date:  2015-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.